MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
31.89
-0.33
-1.02%
Pre Market: 31.85 -0.04 -0.13% 07:48 02/13 EST
OPEN
32.95
PREV CLOSE
32.22
HIGH
33.28
LOW
31.47
VOLUME
7.35K
TURNOVER
0
52 WEEK HIGH
38.69
52 WEEK LOW
5.35
MARKET CAP
1.82B
P/E (TTM)
48.32
1D
5D
1M
3M
1Y
5Y
1D
A Look At Stoke Therapeutics (STOK) Valuation After Strong One Year Share Price Momentum
Simply Wall St · 18h ago
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Tenet Healthcare (THC) and Stoke Therapeutics (STOK)
TipRanks · 1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Stoke Therapeutics Doses The First Patient In Phase 1 OSPREY Study Of STK-002 For Autosomal Dominant Optic Atrophy
Benzinga · 2d ago
Stoke Therapeutics Doses First Patient in Phase 1 Trial of STK-002 for Autosomal Dominant Optic Atrophy
Reuters · 2d ago
STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTS
Reuters · 2d ago
Weekly Report: what happened at STOK last week (0202-0206)?
Weekly Report · 4d ago
Stoke Therapeutics initiated with a Buy at Guggenheim
TipRanks · 02/05 10:00
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.